Analysis of Linked Health Insurance Claims and Clinical Registries to Determine Device Surveillance With Paclitaxel-coated Medical Devices
NCT04683458 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 14000
Last updated 2021-01-15
Summary
The GermanVasc/MDEpiNet Paclitaxel Study, aims to use routinely collected data from health insurance claims and registries. The longitudinal data of Germany's second-largest insurance fund, BARMER, includes the outpatient and inpatient medical care provided to ≈9.4 million German citizens (13.2% of Germany's population) involving \>21 million hospitalizations between January 1, 2008, and December 31, 2018. The BARMER cohort is similar to Western European countries and has been widely used for research projects. A regular random sample validation of internal and external validity is performed by the Medical Service of the Health Funds in Germany, and various peer-reviewed validation studies have been previously published. The GermanVasc clinical registry was implemented in 2018 as EU General Data Protection Regulation (GDPR) compliant registry platform to process routinely collected clinical data from more than 35 high-volume vascular centers in Germany. In an ongoing project of a large multispecialty and multidisciplinary research consortium (RABATT study, Principal Investigator: PD Dr. Christian-Alexander Behrendt), active surveillance and medical device evaluation methods were developed. The current study aims to determine the long-term safety and efficacy of paclitaxel-coated balloons and stents in peripheral arteries. It further aims to illuminate the underlying differences between the cohorts in randomized controlled trials (RCT) and real-world data that can possibly explain the diametrically opposed results in an ongoing international controversy.
Conditions
- Paclitaxel Adverse Reaction
- Outcome, Fatal
Interventions
- DEVICE
-
Drug-coated device
The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
Sponsors & Collaborators
-
GermanVasc
collaborator OTHER -
BARMER
collaborator OTHER -
MDEpiNet Verband Deutschland e.V.
collaborator UNKNOWN -
Universitätsklinikum Hamburg-Eppendorf
lead OTHER
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-01-31
- Primary Completion
- 2021-02-28
- Completion
- 2021-02-28
- FDA Device
- Yes
More Related Trials
-
Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)
NCT05322889 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
NCT02789332 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
NCT00398489 ·Status: UNKNOWN ·Phase: PHASE2
-
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
NCT01049425 ·Status: COMPLETED ·Phase: PHASE3
-
Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes
NCT00668616 ·Status: COMPLETED ·Phase: PHASE3
-
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
NCT01320111 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
NCT01740336 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
NCT00721409 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
NCT00900627 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer
NCT00748553 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
NCT00320541 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
NCT01352494 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases
NCT02603679 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT00461344 ·Status: TERMINATED ·Phase: PHASE2
-
Docetaxel in Node Positive Adjuvant Breast Cancer
NCT00688740 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response
NCT02214381 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Novel Thoracic Wall Blocks With Dexmetomidine on Inflammatory Markers Following Breast Cancer Surgery
NCT04860115 ·Status: UNKNOWN ·Phase: NA
-
Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.
NCT06387901 ·Status: RECRUITING
-
Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer
NCT00538525 ·Status: COMPLETED ·Phase: NA
-
Clinical Study of Decitabine and Paclitaxel Combination Therapy
NCT03282825 ·Status: UNKNOWN ·Phase: PHASE1
-
Docetaxel in Breast Cancer
NCT00312208 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
NCT00669591 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
NCT02907918 ·Status: TERMINATED ·Phase: PHASE2
-
Acute Pain Caused by Paclitaxel in Patients With Cancer
NCT00860041 ·Status: COMPLETED
-
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
NCT00433511 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3